Superficial Cortical Aβ Clearance and ARIA Pathology in Aducanumab‐Treated Alzheimer's Disease

Abstract

Background: Monoclonal antibodies targeting amyloid‐β (Aβ), including aducanumab, have been tested to treat Alzheimer's disease (AD). However, limited data exist on neuropathology following treatment and the effects of amyloid‐related imaging abnormalities (ARIA).

The paper